VIDEO: Breast Cancer Clinical Trial Breakthroughs - Updates from ASCO 2025

Editor’s Note: In 2025, the FDA approved Inluriyo™ (imlunestrant), an oral selective estrogen receptor degrader (SERD), for ER-positive, HER2-negative, ESR1-mutated, second-line advanced or metastatic breast cancer.

Welcome to our special report covering the most significant advancements from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In the video below, we will unpack 3 pivotal Phase 3 trials – addressing HER2-positive, triple-negative, and hormone-receptor-positive breast cancers – that are set to redefine current treatment guidelines and improve patient outcomes across the board.

This video was generated with the assistance of an AI tool and reviewed by a member of our Editorial Team and Health Union Medical Review Board. This information is provided for general knowledge and is not a substitute for professional medical advice.